OROS residence time [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2012-09-13 16:28 (5033 d 16:31 ago) – Posting: # 9200
Views: 7,239

Hi ABE1580!

❝ Dear Sir,

    Not interested in madams’ opinions?


❝ Will it be acceptable to the FDA; if we keep option of excluding the volunteer based on the residence time of dosage form in GIT in case of Osmotic drug delivery system (ODDS)?


No way.

❝ […] In case of ODDS the tablets stay for more time in GIT and that leads to variability. Say in case of Test product tablets, it was there in GIT till 33 hrs and after that it was expelled in feces. But in same volunteer; the reference product expelled after 46 hrs.


BE is a surrogate of clinical efficacy. You can’t ignore variability caused by the formulation itself or the motility of the GIT. Does the label of OROS state “check your feces daily – if you don’t find a tablet there, see your physician”?

❝ So, will it be acceptable to FDA, if we predefine the exclusion criteria "The subjects will be excluded from the bioequivalence evaluation; who do not expel the tablets within 42 hrs"


No.

❝ Any such type of observation any one came accross?


I stopped peeking into my feces a long time ago. GIT in non-vegetarians is ≤72 hours (BTW, this is the rationale behind AUC72 for IR formulations). Gastric motility in vegetarians might be decreased;* I would suggest to include non-vegetarians in the study.



Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
161 visitors (0 registered, 161 guests [including 43 identified bots]).
Forum time: 08:59 CEST (Europe/Vienna)

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5